Search

Displaying results 2111 - 2120 of 4190 in total
  1. Drug

    Resmetirom

    go.drugbank.com/drugs/DB12914
    ApprovedInvestigational

    Resmetirom is a thyroid hormone receptor-beta (THR-beta) agonist. On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alc...

  2. Drug

    Nabilone

    go.drugbank.com/drugs/DB00486
    ApprovedInvestigational

    Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmac...

  3. Drug

    Tenofovir disoproxil

    go.drugbank.com/drugs/DB00300
    ApprovedInvestigational

    Tenofovir disoproxil fumarate (a prodrug of tenofovir), marketed by Gilead Sciences under the trade name Viread, belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (nRTIs). This drug ...

  4. Drug

    Levosimendan

    go.drugbank.com/drugs/DB00922
    ApprovedInvestigationalWithdrawn

    Levosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels. It also relaxes vascular smooth muscle by opening adenosine triph...

  5. Drug

    Mibefradil

    go.drugbank.com/drugs/DB01388
    ApprovedWithdrawn

    Mibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.

  6. Drug

    Defibrotide

    go.drugbank.com/drugs/DB04932
    ApprovedInvestigational

    It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects).

  7. Drug

    Etifoxine

    go.drugbank.com/drugs/DB08986
    ApprovedWithdrawn

    Etifoxine has been associated with acute liver injury.

  8. Drug

    D-Tryptophan

    go.drugbank.com/drugs/DB03225
    Experimental

    It is an essential amino acid as defined by its growth effects on rats.

  9. Drug

    Desmoteplase

    go.drugbank.com/drugs/DB04925
    Investigational

    Plasmin acts by breaking down fibrin blood clots. When a vampire bat bites its victim, it secretes an enzyme that prevents the blood from clotting.

  10. Drug

    Camostat

    go.drugbank.com/drugs/DB13729
    Investigational

    Camostat mesylate, or FOY-305, is a synthetic serine protease inhibitor. It was first described in the literature in 1981, as part of research on the inhibition of skin tumors in mice. Camostat mesylate inhibits cholecystokinin, pro-infl...